Published in Cancer Weekly, August 30th, 2005
"Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. ADT, specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease," scientists in the United States reported.
"To review systematically the evidence on the risks and benefits of ADT for prostate cancer as well as clinical management of its adverse effects, we performed MEDLINE searches of English-language literature (1966 to March 2005) using the terms...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.